ALX Oncology announces first patient dosed in ASPEN-07 study

ALX Oncology announced the first patient has been dosed in the ASPEN-07 study evaluating evorpacept, a next generation CD47 blocker, in combination with PADCEV, an antibody drug conjugate, ADC, in patients with urothelial cancer, UC. "Outcomes for patients diagnosed with locally advanced or metastatic UC remain poor, and treatment options after initial chemotherapy and immunotherapy are limited," said Sophia Randolph, M.D., Ph.D., ALX Oncology’s Chief Medical Officer. "We are excited to initiate ASPEN-07 to investigate this novel combination therapy that has the potential to change the treatment course of advanced UC. We are encouraged that PADCEV is the first ADC therapy to demonstrate meaningful clinical activity in these difficult-to-treat patients, and the addition of a CD47 blocker is expected to act through different but complementary mechanisms to positively impact efficacy without increasing toxicity."